Chad M. Centner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chad M. Centner has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Jeannine M. Heckmann
UCT Neuroscience Institute, University of Cape Town, South Africa
3 shared publications - Bianca Sossen
Department of Medicine, Faculty of Health Sciences, University of Cape Town , Cape Town
2 shared publications - Clinton Moodley
Department of Pathology, Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
2 shared publications - Colleen Bamford
Universiteit van Kaapstad
2 shared publications - Graeme Meintjes
Department of Medicine, University of Cape Town , Cape Town
2 shared publications - Marcia Vermeulen
Department of Medicine, University of Cape Town , Cape Town
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Prevalence and Mortality due to Mycobacterium tuberculosis Bloodstream Infection in Adults With HIV: A Multicountry Prospective Cohort Study
Background: HIV-associated tuberculosis is a leading cause of mortality. Mycobacterium tuberculosis bloodstream infection (MTB-BSI) is complicated by diagnostic difficulty and severe illness. We assessed whether MTB-BSI continues to be common in the era of widespread antiretroviral therapy and whether it continues to result in increased risk of early mortality. Methods: We enrolled inpatients from medical wards irrespective of tuberculosis symptoms and outpatients with tuberculosis symptoms. All participants had HIV and were ≥18 years old, and all were recruited from 7 countries: Malawi, South Africa, Tanzania, Thailand, Uganda, Vietnam, and Zambia. Participants also had <3 doses of antituberculosis treatment in the past 60 days and no isoniazid preventive therapy in the past 6 months. We estimated the prevalence of MTB-BSI. In Bayesian survival models, we estimated the hazards of mortality for inpatients with MTB-BSI vs those without. Results: Between 2019 and 2021, 1703 participants were included: 44% were hospitalized, the median CD4 count was 361 cells/μL, and 77% reported using antiretroviral therapy. Crude prevalence of MTB-BSI varied by country but was 4.4% (32/723) among all inpatients, 22.5% (32/142) among inpatients with microbiologically confirmed TB, and 0.2% (2/913) among all outpatients. Among all inpatients, those with MTB-BSI had 2.65-times (95% credible interval, 1.06–5.01) increased hazard of death by 30 days and 1.79-times (95% credible interval, .81–3.11) increased hazard by 70 days. Lower CD4 and older age were strongly associated with mortality. Conclusions: MTB-BSI is far more common for inpatients than outpatients with HIV. Across multiple settings with high tuberculosis prevalence, MTB-BSI was strongly associated with heightened risk of early mortality in PWH. Novel optimized diagnostic and treatment strategies are still needed for HIV-associated MTB-BSI.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessPrevalence and Mortality due to Mycobacterium tuberculosis Bloodstream Infection in Adults With HIV: A Multicountry Prospective Cohort Study
Background: HIV-associated tuberculosis is a leading cause of mortality. Mycobacterium tuberculosis bloodstream infection (MTB-BSI) is complicated by diagnostic difficulty and severe illness. We assessed whether MTB-BSI continues to be common in the era of widespread antiretroviral therapy and whether it continues to result in increased risk of early mortality. Methods: We enrolled inpatients from medical wards irrespective of tuberculosis symptoms and outpatients with tuberculosis symptoms. All participants had HIV and were ≥18 years old, and all were recruited from 7 countries: Malawi, South Africa, Tanzania, Thailand, Uganda, Vietnam, and Zambia. Participants also had <3 doses of antituberculosis treatment in the past 60 days and no isoniazid preventive therapy in the past 6 months. We estimated the prevalence of MTB-BSI. In Bayesian survival models, we estimated the hazards of mortality for inpatients with MTB-BSI vs those without. Results: Between 2019 and 2021, 1703 participants were included: 44% were hospitalized, the median CD4 count was 361 cells/μL, and 77% reported using antiretroviral therapy. Crude prevalence of MTB-BSI varied by country but was 4.4% (32/723) among all inpatients, 22.5% (32/142) among inpatients with microbiologically confirmed TB, and 0.2% (2/913) among all outpatients. Among all inpatients, those with MTB-BSI had 2.65-times (95% credible interval, 1.06–5.01) increased hazard of death by 30 days and 1.79-times (95% credible interval, .81–3.11) increased hazard by 70 days. Lower CD4 and older age were strongly associated with mortality. Conclusions: MTB-BSI is far more common for inpatients than outpatients with HIV. Across multiple settings with high tuberculosis prevalence, MTB-BSI was strongly associated with heightened risk of early mortality in PWH. Novel optimized diagnostic and treatment strategies are still needed for HIV-associated MTB-BSI.
- 20 November 2025
- Published by Elsevier in Trends in Microbiology
- Vol. 34 (1) , 24-25
Advancing equity in antimicrobial resistance research and policy
- 20 November 2025
- Published by Elsevier in Trends in Microbiology
- Vol. 34 (1) , 24-25
Advancing equity in antimicrobial resistance research and policy
- Open Access
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis
Background: Treatment response biomarkers are needed in the care of patients hospitalised with HIV-associated tuberculosis (TB). Objectives: We describe the changes in bacillary load during early treatment using quantitative and semi-quantitative measures of Mycobacterium tuberculosis in blood and urine. Method: We collected serial blood and urine samples at multiple timepoints in consenting adult patients with HIV and positive urine lipoarabinomannan (LAM), admitted to Mitchells Plain Hospital, Cape Town. Blood and urine Xpert Ultra, mycobacterial blood culture and urine LAM were performed. Survival analysis and mixed-effects modelling were used to determine time to a negative test, and to give the predicted probability of a positive test at the different timepoints. Results: Sixteen participants, predominantly male (63%), with median age 39 years (interquartile range [IQR] 36–43), and CD4 count 27 cells/mm3 (IQR 8–83) were included. At day 14, urine LAM, urine Xpert Ultra and blood Xpert Ultra remained positive in between 75% and 86% of the participants. A mixed-effects model predicted a decline in ordinal values of urine Xpert Ultra (cycle threshold), blood Xpert Ultra (cycle threshold) and blood culture (time-to-positivity) in response to anti-TB treatment. Conversely, urine LAM grade intensity increased over the 14 days. Conclusion: M. tuberculosis DNA was detectable in urine and blood in decreasing quantity up to 14 days of standard treatment in patients with HIV-associated TB. Urine Alere LAM showed an increasing grade intensity during this period. Further research in larger groups and extended periods are needed to assess relation to clinical outcomes.
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
Open AccessBlood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis
Background: Treatment response biomarkers are needed in the care of patients hospitalised with HIV-associated tuberculosis (TB). Objectives: We describe the changes in bacillary load during early treatment using quantitative and semi-quantitative measures of Mycobacterium tuberculosis in blood and urine. Method: We collected serial blood and urine samples at multiple timepoints in consenting adult patients with HIV and positive urine lipoarabinomannan (LAM), admitted to Mitchells Plain Hospital, Cape Town. Blood and urine Xpert Ultra, mycobacterial blood culture and urine LAM were performed. Survival analysis and mixed-effects modelling were used to determine time to a negative test, and to give the predicted probability of a positive test at the different timepoints. Results: Sixteen participants, predominantly male (63%), with median age 39 years (interquartile range [IQR] 36–43), and CD4 count 27 cells/mm3 (IQR 8–83) were included. At day 14, urine LAM, urine Xpert Ultra and blood Xpert Ultra remained positive in between 75% and 86% of the participants. A mixed-effects model predicted a decline in ordinal values of urine Xpert Ultra (cycle threshold), blood Xpert Ultra (cycle threshold) and blood culture (time-to-positivity) in response to anti-TB treatment. Conversely, urine LAM grade intensity increased over the 14 days. Conclusion: M. tuberculosis DNA was detectable in urine and blood in decreasing quantity up to 14 days of standard treatment in patients with HIV-associated TB. Urine Alere LAM showed an increasing grade intensity during this period. Further research in larger groups and extended periods are needed to assess relation to clinical outcomes.
- Open Access
- 15 September 2023
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 34 (2) , 815-821
Developing an antibiogram for empiric antibiotic prescribing for adult non-spinal orthopaedic infections in a developing world setting
Purpose: Empiric antibiotic strategies in the treatment of fracture-related infections, chronic osteomyelitis, prosthetic joint infection, and septic arthritis should be based on local microbiological antibiograms. This study aims to describe the microbiology and review the antibiogram profiles of bacterial isolates from patients undergoing surgical treatment for non-spinal orthopaedic infections, to identify the most appropriate empiric antibiotic strategy.Methods: A retrospective review was performed of all cases of non-spinal orthopaedic infections treated surgically from 1 January 2018 to 31 December 2018. The National Health Laboratory Service microbiology database was used to identify all intra-operative microbiological specimens obtained from orthopaedic patients, and data were correlated with the orthopaedic surgical database. Cases were divided into fracture-related infections, chronic osteomyelitis, prosthetic joint infection, and septic arthritis. Antibiotic susceptibility data were used to predict the efficacy of different empiric antibiotic regimens.Results: A total of 107 cases were included in the study; 184 organisms were cultured. Overall, the most common organism cultured wasStaphylococcus aureus(25%) followed byAcinetobacter baumannii(9%),Enterococcus faecalis(7%) andEnterobacter cloacae(5%). Across all categories the oral antibiotic combination with the highest effectiveness (81%) would have been a combination of co-trimoxazole, ciprofloxacin and amoxicillin. The most effective intravenous antibiotic combination would have been either piperacillin–tazobactam, amikacin and vancomycin or meropenem and vancomycin; 90% of tested isolates were susceptible to either of these combinations.Conclusion: Antibiogram profiles can serve to guide to empiric antibiotic choice in the management of different categories of non-spinal orthopaedic infections.
- 15 September 2023
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 34 (2) , 815-821
Open AccessDeveloping an antibiogram for empiric antibiotic prescribing for adult non-spinal orthopaedic infections in a developing world setting
Purpose: Empiric antibiotic strategies in the treatment of fracture-related infections, chronic osteomyelitis, prosthetic joint infection, and septic arthritis should be based on local microbiological antibiograms. This study aims to describe the microbiology and review the antibiogram profiles of bacterial isolates from patients undergoing surgical treatment for non-spinal orthopaedic infections, to identify the most appropriate empiric antibiotic strategy.Methods: A retrospective review was performed of all cases of non-spinal orthopaedic infections treated surgically from 1 January 2018 to 31 December 2018. The National Health Laboratory Service microbiology database was used to identify all intra-operative microbiological specimens obtained from orthopaedic patients, and data were correlated with the orthopaedic surgical database. Cases were divided into fracture-related infections, chronic osteomyelitis, prosthetic joint infection, and septic arthritis. Antibiotic susceptibility data were used to predict the efficacy of different empiric antibiotic regimens.Results: A total of 107 cases were included in the study; 184 organisms were cultured. Overall, the most common organism cultured wasStaphylococcus aureus(25%) followed byAcinetobacter baumannii(9%),Enterococcus faecalis(7%) andEnterobacter cloacae(5%). Across all categories the oral antibiotic combination with the highest effectiveness (81%) would have been a combination of co-trimoxazole, ciprofloxacin and amoxicillin. The most effective intravenous antibiotic combination would have been either piperacillin–tazobactam, amikacin and vancomycin or meropenem and vancomycin; 90% of tested isolates were susceptible to either of these combinations.Conclusion: Antibiogram profiles can serve to guide to empiric antibiotic choice in the management of different categories of non-spinal orthopaedic infections.
- Open Access
Something from nothing: Sensitivity and specificity of Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection
Background: Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, USA) is a widely-used rapid front-line TB and rifampicin susceptibility test. Mycobacterium Growth Indicator Tube 960 (MGIT960) culture is still used as an adjunct for tuberculosis (TB) and drug susceptibility diagnosis but is vulnerable to contamination. Whether Ultra can be used on to-be-discarded contaminated cultures is uninvestigated. Methods: We stored contaminated MGIT960 tubes (growth-positive, acid-fast-bacilli-negative) inoculated to diagnose pulmonary TB in a routine high-volume laboratory in Cape Town, South Africa. Patients who had, at contamination-detection, no positive TB results (smear, Ultra, culture) and another specimen submitted three months post-contaminated specimen submission were selected. We evaluated the sensitivity and specificity of Ultra on contaminated growth from the first culture for 1) TB (next-available non-contaminated culture result reference standard), and 2) rifampicin resistance (vs. MTBDR plus on the later isolate). We calculated potential time-to-diagnosis improvements. We also evaluated MPT64 TBc (TBc). Findings: 2186 patients had a contaminated diagnostic culture. 49% (1068/2186) had no other specimen submitted, despite guidance to the contrary. After 319 ineligible patients were excluded, 799 with at least one repeat specimen submitted remained: 31% (n=246), 54% (n=429) and 16% (n=124) were repeat-specimen culture-positive, -negative, and -contaminated, respectively. When Ultra was done on the initial contaminated growth, sensitivity and specificity were 89% (95% CI 84-94) and 95% (90-98) for TB and 95% (75-100) and 98% (93-100) for rifampicin-resistance. If our approach were performed the day after initial contamination detection, time-to-TB-detection would improve a median (IQR) of 23 (13-45) days and, importantly, provide a result in many patients who had none. TBc had poor accuracy. Conclusion: Ultra on acid-fast-negative growth from contaminated MGIT960 tubes had high sensitivity and specificity; approximating World Health Organization-target product performance sputum test and exceeding drug susceptibility testing (DST) criteria. Our approach could mitigate contamination’s negative effects, especially when repeat specimens are not submitted. Research in context: Evidence before this study: Improving the diagnosis of tuberculosis (TB) and drug-resistance through strengthening the laboratory care cascade is a public health priority. Scale-up of molecular tests like Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, USA), for the upfront diagnosis of TB and rifampicin-resistance has doubtlessly improved the care cascade, however, culture, despite several limitations, continues to be used for the diagnosis and susceptibility testing for technical, historic, and cost reasons (the most common TB culture platform is the MGIT960 liquid culture system). The fact that global TB diagnosis still, in part, relies on culture means that culture-contamination, which represents a failed attempt at testing, worsens care cascade gaps. Contamination requires another specimen to be collected from patients, however, this causes delays or complete care cascade drop out of patients. Contaminated cultures are traditionally checked with microscopy to see if they contain acid-fast bacilli (AFB), however, the use of Ultra on contaminated cultures, especially those who are AFB-negative, is unexplored. If performance is high, the negative impact of culture-contamination, which is frequent in many settings, could be drastically mitigated as Ultra is widely-available. Added value of this study: We showed that Ultra on to-be discarded contaminated MGIT960 cultures can detect TB in a highly sensitive and specific manner (89% sensitivity, 95% specificity). It also had excellent sensitivity and specificity for rifampicin resistance (95% sensitivity, 98% specificity). Performance levels exceeded those accepted by the World Health Organization for Ultra done directly on respiratory specimens. In patients who, after initial culture contamination had another specimen submitted for culture, our approach could reduce time to diagnosis by approximately 23 days. Critically, many patients with contamination had, despite programmatic guidance, no record of a further attempt to diagnose TB (44%), and in these patients our Ultra on contaminated cultures approach would result in an accurate TB and rifampicin-resistance result where none would ordinarily occur. Implications of all available evidence: When done on contaminated MGIT960 culture growth resulting from a failed attempt to diagnose TB, Ultra has excellent performance for TB and rifampicin-resistance detection and would likely reduce the impact of culture-contamination on the diagnostic care cascade. Laboratories should consider evaluating and potentially implementing this approach wherever TB culture is done for diagnostic purposes.
Open AccessSomething from nothing: Sensitivity and specificity of Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection
Background: Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, USA) is a widely-used rapid front-line TB and rifampicin susceptibility test. Mycobacterium Growth Indicator Tube 960 (MGIT960) culture is still used as an adjunct for tuberculosis (TB) and drug susceptibility diagnosis but is vulnerable to contamination. Whether Ultra can be used on to-be-discarded contaminated cultures is uninvestigated. Methods: We stored contaminated MGIT960 tubes (growth-positive, acid-fast-bacilli-negative) inoculated to diagnose pulmonary TB in a routine high-volume laboratory in Cape Town, South Africa. Patients who had, at contamination-detection, no positive TB results (smear, Ultra, culture) and another specimen submitted three months post-contaminated specimen submission were selected. We evaluated the sensitivity and specificity of Ultra on contaminated growth from the first culture for 1) TB (next-available non-contaminated culture result reference standard), and 2) rifampicin resistance (vs. MTBDR plus on the later isolate). We calculated potential time-to-diagnosis improvements. We also evaluated MPT64 TBc (TBc). Findings: 2186 patients had a contaminated diagnostic culture. 49% (1068/2186) had no other specimen submitted, despite guidance to the contrary. After 319 ineligible patients were excluded, 799 with at least one repeat specimen submitted remained: 31% (n=246), 54% (n=429) and 16% (n=124) were repeat-specimen culture-positive, -negative, and -contaminated, respectively. When Ultra was done on the initial contaminated growth, sensitivity and specificity were 89% (95% CI 84-94) and 95% (90-98) for TB and 95% (75-100) and 98% (93-100) for rifampicin-resistance. If our approach were performed the day after initial contamination detection, time-to-TB-detection would improve a median (IQR) of 23 (13-45) days and, importantly, provide a result in many patients who had none. TBc had poor accuracy. Conclusion: Ultra on acid-fast-negative growth from contaminated MGIT960 tubes had high sensitivity and specificity; approximating World Health Organization-target product performance sputum test and exceeding drug susceptibility testing (DST) criteria. Our approach could mitigate contamination’s negative effects, especially when repeat specimens are not submitted. Research in context: Evidence before this study: Improving the diagnosis of tuberculosis (TB) and drug-resistance through strengthening the laboratory care cascade is a public health priority. Scale-up of molecular tests like Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, USA), for the upfront diagnosis of TB and rifampicin-resistance has doubtlessly improved the care cascade, however, culture, despite several limitations, continues to be used for the diagnosis and susceptibility testing for technical, historic, and cost reasons (the most common TB culture platform is the MGIT960 liquid culture system). The fact that global TB diagnosis still, in part, relies on culture means that culture-contamination, which represents a failed attempt at testing, worsens care cascade gaps. Contamination requires another specimen to be collected from patients, however, this causes delays or complete care cascade drop out of patients. Contaminated cultures are traditionally checked with microscopy to see if they contain acid-fast bacilli (AFB), however, the use of Ultra on contaminated cultures, especially those who are AFB-negative, is unexplored. If performance is high, the negative impact of culture-contamination, which is frequent in many settings, could be drastically mitigated as Ultra is widely-available. Added value of this study: We showed that Ultra on to-be discarded contaminated MGIT960 cultures can detect TB in a highly sensitive and specific manner (89% sensitivity, 95% specificity). It also had excellent sensitivity and specificity for rifampicin resistance (95% sensitivity, 98% specificity). Performance levels exceeded those accepted by the World Health Organization for Ultra done directly on respiratory specimens. In patients who, after initial culture contamination had another specimen submitted for culture, our approach could reduce time to diagnosis by approximately 23 days. Critically, many patients with contamination had, despite programmatic guidance, no record of a further attempt to diagnose TB (44%), and in these patients our Ultra on contaminated cultures approach would result in an accurate TB and rifampicin-resistance result where none would ordinarily occur. Implications of all available evidence: When done on contaminated MGIT960 culture growth resulting from a failed attempt to diagnose TB, Ultra has excellent performance for TB and rifampicin-resistance detection and would likely reduce the impact of culture-contamination on the diagnostic care cascade. Laboratories should consider evaluating and potentially implementing this approach wherever TB culture is done for diagnostic purposes.
- Open Access
- 22 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 117, 74-86
A citywide, clonal outbreak of Pseudomonas aeruginosa
- 22 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 117, 74-86
Open AccessA citywide, clonal outbreak of Pseudomonas aeruginosa
- Open Access
- 19 January 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 398
Xpert MTB/RIF Ultra and mycobacterial culture in routine clinical care at a paediatric hospital
Background: Microbiological confirmation of pulmonary tuberculosis (PTB) in children is a well-documented challenge. This study evaluated Xpert Mycobacterium Tuberculosis (MTB)/Rifampicin (RIF) Ultra (Ultra) and mycobacterial cultures in routine clinical care at a tertiary paediatric hospital. Methods: Children treated for PTB and who had at least one respiratory specimen investigated by Ultra and mycobacterial culture before tuberculosis (TB) treatment was commenced were included. The findings of this retrospective study were summarised using descriptive and inferential statistics. Results: A total of 174 children were included. The median age was 2.5 years. Microcytic anaemia, airway compression, cavitary disease and miliary TB were significantly observed in children with microbiologically confirmed TB (cTB). Tuberculosis was microbiologically confirmed in 93 (53.4%) children. The positive yield from testing the first respiratory specimens was 68/174 (39.1%) on Ultra and 82/174 (47.1%) on combined Ultra and mycobacterial culture. In the subset of children (n = 70) tested with Ultra on two sequential respiratory specimens, the incremental yield from the second specimen was 30.3%. In the subset of children (n = 16) tested with Ultra on three sequential respiratory specimens, the incremental yield from the second and third specimens was 16.7% and 0.0%, respectively. When Ultra and mycobacterial culture results were combined, the incremental yield in children who had two sequential respiratory specimens tested was 24.4% and 3.1% on Ultra and mycobacterial culture, respectively. Conclusion: Ultra and mycobacterial culture on a single respiratory specimen resulted in a high microbiological yield. Ultra-testing on a second respiratory specimen increased the yield of microbiologically cTB. Additional diagnostic testing may require further study.
- 19 January 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 398
Open AccessXpert MTB/RIF Ultra and mycobacterial culture in routine clinical care at a paediatric hospital
Background: Microbiological confirmation of pulmonary tuberculosis (PTB) in children is a well-documented challenge. This study evaluated Xpert Mycobacterium Tuberculosis (MTB)/Rifampicin (RIF) Ultra (Ultra) and mycobacterial cultures in routine clinical care at a tertiary paediatric hospital. Methods: Children treated for PTB and who had at least one respiratory specimen investigated by Ultra and mycobacterial culture before tuberculosis (TB) treatment was commenced were included. The findings of this retrospective study were summarised using descriptive and inferential statistics. Results: A total of 174 children were included. The median age was 2.5 years. Microcytic anaemia, airway compression, cavitary disease and miliary TB were significantly observed in children with microbiologically confirmed TB (cTB). Tuberculosis was microbiologically confirmed in 93 (53.4%) children. The positive yield from testing the first respiratory specimens was 68/174 (39.1%) on Ultra and 82/174 (47.1%) on combined Ultra and mycobacterial culture. In the subset of children (n = 70) tested with Ultra on two sequential respiratory specimens, the incremental yield from the second specimen was 30.3%. In the subset of children (n = 16) tested with Ultra on three sequential respiratory specimens, the incremental yield from the second and third specimens was 16.7% and 0.0%, respectively. When Ultra and mycobacterial culture results were combined, the incremental yield in children who had two sequential respiratory specimens tested was 24.4% and 3.1% on Ultra and mycobacterial culture, respectively. Conclusion: Ultra and mycobacterial culture on a single respiratory specimen resulted in a high microbiological yield. Ultra-testing on a second respiratory specimen increased the yield of microbiologically cTB. Additional diagnostic testing may require further study.
- Open Access
Sentinel seroprevalence of SARS-CoV-2 in the Gauteng province, South Africa August to October 2020
Background Estimates of prevalence of anti-SARS-CoV-2 antibody positivity (seroprevalence) are for tracking the Covid-19 epidemic and are lacking for most African countries. Objectives To determine the prevalence of antibodies against SARS-CoV2 in a sentinel cohort of patient samples received for routine testing at tertiary laboratories in Johannesburg, South Africa Methods This sentinel study was conducted using remnant serum samples received at three National Health Laboratory Services laboratories situated in the City of Johannesburg (COJ) district, South Africa. Collection was from 1 August until the 31 October 2020. We extracted accompanying laboratory results for haemoglobin A1c, creatinine, HIV, viral load, and CD4+ T cell count. An anti-SARS -CoV-2 targeting the nucleocapsid (N) protein of the coronavirus with higher affinity for IgM and IgG antibodies was used. We reported crude as well as population weighted and test adjusted seroprevalence. Multivariate logistic regression method was used to determine if age, sex, HIV and diabetic status were associated with increased risk for seropositivity. Results A total of 6477 samples were analysed; the majority (5290) from the COJ region. After excluding samples with no age or sex stated, the model population weighted and test adjusted seroprevalence for COJ (N=4393) was 27.0 % (95% CI: 25.4-28.6%). Seroprevalence was highest in those aged 45-49 [29.8% (95% CI: 25.5-35.0 %)] and in those from the most densely populated areas of COJ. Risk for seropositivity was highest in those aged 18-49 as well as samples from diabetics (aOR =1.52; 95% CI: 1.13-2.13; p=0.0005) and (aOR=1.36; 95% CI: 1.13-1.63; p=0.001) respectively. Conclusion Our study conducted during the first wave of the pandemic shows high levels of infection among patients attending public health facilities in Gauteng.
Open AccessSentinel seroprevalence of SARS-CoV-2 in the Gauteng province, South Africa August to October 2020
Background Estimates of prevalence of anti-SARS-CoV-2 antibody positivity (seroprevalence) are for tracking the Covid-19 epidemic and are lacking for most African countries. Objectives To determine the prevalence of antibodies against SARS-CoV2 in a sentinel cohort of patient samples received for routine testing at tertiary laboratories in Johannesburg, South Africa Methods This sentinel study was conducted using remnant serum samples received at three National Health Laboratory Services laboratories situated in the City of Johannesburg (COJ) district, South Africa. Collection was from 1 August until the 31 October 2020. We extracted accompanying laboratory results for haemoglobin A1c, creatinine, HIV, viral load, and CD4+ T cell count. An anti-SARS -CoV-2 targeting the nucleocapsid (N) protein of the coronavirus with higher affinity for IgM and IgG antibodies was used. We reported crude as well as population weighted and test adjusted seroprevalence. Multivariate logistic regression method was used to determine if age, sex, HIV and diabetic status were associated with increased risk for seropositivity. Results A total of 6477 samples were analysed; the majority (5290) from the COJ region. After excluding samples with no age or sex stated, the model population weighted and test adjusted seroprevalence for COJ (N=4393) was 27.0 % (95% CI: 25.4-28.6%). Seroprevalence was highest in those aged 45-49 [29.8% (95% CI: 25.5-35.0 %)] and in those from the most densely populated areas of COJ. Risk for seropositivity was highest in those aged 18-49 as well as samples from diabetics (aOR =1.52; 95% CI: 1.13-2.13; p=0.0005) and (aOR=1.36; 95% CI: 1.13-1.63; p=0.001) respectively. Conclusion Our study conducted during the first wave of the pandemic shows high levels of infection among patients attending public health facilities in Gauteng.
- Open Access
- 15 April 2021
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 36 (1) , 9
The BinaxNOW pneumococcal antigen test: An adjunct for diagnosis of pneumococcal bacteraemia
Background: Culture remains the diagnostic standard for Streptococcus pneumoniae bacteraemia but is limited by time to identification, prior antibiotics and bacterial autolysis. Culture-independent methods for detecting S. pneumoniae include PCR and antigen tests. We evaluated an antigen test on blood culture broth for the rapid detection of S. pneumoniae bacteraemia. Method: We collected 212 signal-positive blood cultures, with gram-positive cocci in pairs, chains or with uncertain morphology. The BinaxNOW S. pneumoniae urinary antigen test, Gram stain, culture and lytA PCR were performed on all samples. Diagnostic accuracy of the antigen test and Gram stain with gram-positive cocci in pairs were compared with culture, polymerase chain reaction (PCR) and the composite of culture and PCR. Results: Streptococcus pneumoniae was isolated in 26% of samples, 66% cultured other gram-positive organisms and 8% of samples had no growth. Sensitivity and negative predictive values of the antigen test were 100%, specificity and positive predictive values were 87% – 88% and 76% – 81%, but increased to 93% – 96% and 96% – 98% when applied to subsets with gram-positive cocci in pairs, or history compatible with respiratory illness or meningitis. Sensitivity (69% – 75%) and specificity (81%) of Gram stain (gram-positive cocci in pairs) were lower than the antigen test even when applied to the same subsets. Conclusion: Accurate and rapid diagnosis of S. pneumoniae bacteraemia is challenging. Specificity of this antigen test is limited by cross-reactivity with other gram-positive organisms, but could be improved if Gram stain morphology and clinical history are available. The antigen test is a useful adjunct for rapid diagnosis of S. pneumoniae bacteraemia.
- 15 April 2021
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 36 (1) , 9
Open AccessThe BinaxNOW pneumococcal antigen test: An adjunct for diagnosis of pneumococcal bacteraemia
Background: Culture remains the diagnostic standard for Streptococcus pneumoniae bacteraemia but is limited by time to identification, prior antibiotics and bacterial autolysis. Culture-independent methods for detecting S. pneumoniae include PCR and antigen tests. We evaluated an antigen test on blood culture broth for the rapid detection of S. pneumoniae bacteraemia. Method: We collected 212 signal-positive blood cultures, with gram-positive cocci in pairs, chains or with uncertain morphology. The BinaxNOW S. pneumoniae urinary antigen test, Gram stain, culture and lytA PCR were performed on all samples. Diagnostic accuracy of the antigen test and Gram stain with gram-positive cocci in pairs were compared with culture, polymerase chain reaction (PCR) and the composite of culture and PCR. Results: Streptococcus pneumoniae was isolated in 26% of samples, 66% cultured other gram-positive organisms and 8% of samples had no growth. Sensitivity and negative predictive values of the antigen test were 100%, specificity and positive predictive values were 87% – 88% and 76% – 81%, but increased to 93% – 96% and 96% – 98% when applied to subsets with gram-positive cocci in pairs, or history compatible with respiratory illness or meningitis. Sensitivity (69% – 75%) and specificity (81%) of Gram stain (gram-positive cocci in pairs) were lower than the antigen test even when applied to the same subsets. Conclusion: Accurate and rapid diagnosis of S. pneumoniae bacteraemia is challenging. Specificity of this antigen test is limited by cross-reactivity with other gram-positive organisms, but could be improved if Gram stain morphology and clinical history are available. The antigen test is a useful adjunct for rapid diagnosis of S. pneumoniae bacteraemia.
- Open Access
- 1 April 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 105, 688-694
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
- 1 April 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 105, 688-694
Open AccessNeuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis